Clinical trial
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On…
NCT00229684 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00229684 |
|---|---|
| Title | ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) |
| Official title | A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Tesaglitazar, pioglitazone |
| Enrollment | 100 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Sep 30, 2005 |
| Last update posted | Aug 30, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: